ArticlePflugers Archiv : European journal of physiology2008
Cyclooxygenase-2 mediates the delayed cardioprotection induced by hydrogen sulfide preconditioning in isolated rat cardiomyocytes.
Article in Pflugers Archiv : European journal of physiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 59 citations in OpenAlex.
- Hydrogen sulfide as a new therapeutic target of pulmonary hypertension: an overview with update on immunomodulation.Frontiers in pharmacology · 2025Review
- HScience advances · 2024Article
- Exogenous HBioengineered · 2022Article
- Effects of sulfide and polysulfides transmitted by direct or signal transduction-mediated activation of TRPA1 channels.British journal of pharmacology · 2019Review
- Review
- Tissue-Specific Analysis of Pharmacological Pathways.CPT: pharmacometrics & systems pharmacology · 2018Article
- Pharmacological Actions of Hydrogen Sulfide Donors on Sympathetic Neurotransmission in the Bovine Anterior Uvea, In Vitro.Neurochemical research · 2016Article
- Evidence for a functional vasodilatatory role for hydrogen sulphide in the human cutaneous microvasculature.The Journal of physiology · 2015Article
- The role of gasotransmitters NO, H2S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning.British journal of pharmacology · 2015Review
- Role of Hydrogen Sulfide in Ischemia-Reperfusion Injury.Oxidative medicine and cellular longevity · 2015Review
- Antisecretory effect of hydrogen sulfide on gastric acid secretion and the involvement of nitric oxide.BioMed research international · 2014Article
- Nitric oxide synthase inhibition abrogates hydrogen sulfide-induced cardioprotection in mice.Molecular and cellular biochemistry · 2012Article
- H(2)S-releasing aspirin protects against aspirin-induced gastric injury via reducing oxidative stress.PloS one · 2012Article
- Article
- Cardioprotective effects of hydrogen sulfide.Nitric oxide : biology and chemistry · 2011Article
- Effects of hydrogen sulphide on the isolated perfused rat heart.Sultan Qaboos University medical journal · 2011Article
- Article
- Hydrogen sulfide-mediated myocardial pre- and post-conditioning.Expert review of clinical pharmacology · 2011Review
- Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2.Journal of molecular and cellular cardiology · 2010Article
- Novel insights into hydrogen sulfide--mediated cytoprotection.Antioxidants & redox signaling · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We previously reported that hydrogen sulfide (H(2)S) preconditioning (SP) produces cardioprotection in isolated rat cardiomyocytes. The present study was designed to determine the involvement of cyclooxygenase-2 (COX-2) in the SP-induced delayed cardioprotection. Isolated cardiac myocytes were treated with NaHS (100 microM, a H(2)S donor) for 30 min and then cultured for 20 h followed by ischemia/reperfusion insults. SP significantly increased cell viability, percentage of rod-shaped cells, and myocyte contractility after 10 min of reperfusion. Given 30 min before and during lethal ischemia, two selective COX-2 inhibitors, NS-398 and celebrex, abrogated SP-induced cardioprotective effects. Moreover, SP upregulated the expression of COX-2 and increased PGE(2) production in the cardiac myocytes. These effects were significantly attenuated by glibenclamide, an ATP-sensitive K(+) channel (K(ATP)) blocker, and chelerythrine, a selective protein kinase C (PKC) inhibitor, suggesting that activation of both K(ATP) and PKC is required for the stimulation of COX-2. Additionally, NG-nitro-L: -arginine methyl ester, a nitric oxide synthase inhibitor, failed to regulate COX-2 protein expression but inhibited SP-enhanced COX-2 activity and PGE(2) production. In conclusion, we provided the first evidence that SP may produce delayed cardioprotection via K(ATP)/PKC dependent induction of COX-2 expression and via nitric oxide-induced COX-2 activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.